Acura Pharmaceuticals (ACUR)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 9, 2024 03:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acura Pharmaceuticals, Inc. [ACUR]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
ValuEngine Detailed Valuation Report for ACUR
Provider: ValuEngine, Inc
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
FDA Guidance on Developing LIMITx Provided; ADF Vicodin on Deck
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
Acura''s Aversion Abuse-Deterrent Technology Licensed to KemPharm
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
FDA Adds Black Box To Opioid - Benzo Labels ;Highlights Limitx Value
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
LTX-04P Development Remains on Track; Phase 1b to Begin in 4Q''16
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
Cohort 2- Reduction In Opioid Absorption As More Tablets Are Swallowed
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
KemPharm''s Positive AdCom Is Supportive of Acura''s Limitx
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
1Q Inline; PK Results of First Oral Abuse Resistant Opioid Due in June
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
Cohort 1 Shows Buffering Agents Worked, Microparticles Need Reformulating
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
FDA Fast Tracks LTX-04, An Oral Abuse Deterrent Opioid
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acura Pharmaceuticals, Inc.
Industry: Medical - Generic Drugs
Limitx Addresses #1 Route of Opioid Abuse: Oral Misuse
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M